Popular on Amzeal

Similar on Amzeal

ABBO News Latest Reports on ELPIS II Trial Update

Amzeal News/10569024
DUBAI, UAE - Amzeal -- ABBO News, a leading financial news platform, has provided exclusive coverage on the remarkable interim results from Longeveron Inc.'s ELPIS II clinical trial evaluating the investigational regenerative cell therapy Lomecel-B™.

The trial is assessing Lomecel-B for the treatment of hypoplastic left heart syndrome (HLHS), a rare and frequently fatal congenital heart defect in newborns.

According to ABBO News' in-depth reporting, Lomecel-B achieved an unprecedented 100% survival rate in HLHS infants through age 5, with no patient requiring a heart transplant. This outcome represents a potential cure for HLHS, a condition where the left side of the heart is severely underdeveloped at birth. Historically, only 50-60% of HLHS patients survive adolescence despite undergoing a series of traumatic surgical interventions that leave most with chronic heart failure.

The ELPIS II trial builds upon the promising results from the earlier ELPIS I Phase 1 study, which first demonstrated Lomecel-B's ability to improve survival rates. In that trial, 100% of infants treated with Lomecel-B survived to age five without requiring a transplant, marking a vast improvement over the historical 20% mortality rate with standard treatment.

More on Amzeal News
Salman Akhtar, Senior Analyst at ABBO News, has been closely following Longeveron's pioneering research in regenerative medicine. He called the 100% survival rate in the ELPIS II trial "truly breathtaking" and a virtually unheard-of achievement in this pediatric heart failure population. Akhtar highlighted the potential for Lomecel-B to eliminate the need for repeated open-heart surgeries in HLHS children.

"His reporting has closely tracked how Lomecel-B appears to be stimulating the regeneration of new cardiovascular tissues in HLHS patients through its powerful anti-inflammatory and pro-healing properties. The ongoing ELPIS II trial represents a critical step in further evaluating Lomecel-B's safety and efficacy across multiple clinical sites.

Longeveron expects to complete the target enrollment of 36 HLHS infants in the ELPIS II trial by the end of 2024. ABBO News has been at the forefront of providing extensive coverage of these groundbreaking developments. In addition to HLHS, ABBO News is actively monitoring Longeveron's investigations exploring the use of Lomecel-B for other areas of significant unmet medical need, such as Alzheimer's disease and aging frailty.

More on Amzeal News
"Longeveron is truly at the vanguard of regenerative medicine, and ABBO News will remain steadfast in delivering the timeliest and most insightful coverage of their clinical advancements. "Their success could catalyze a renaissance in treating previously incurable conditions - a story our audience has an immense appetite for."

About ABBO News

ABBO News is a leading digital source for up-to-the-minute financial news, stock analysis, and market insights. From biotech investing to finance trends, their seasoned team provides in-depth reporting and expert commentary, helping investors make informed decisions.

Visit ABBO New today!

Source: Abbonews
Filed Under: Technology

Show All News | Report Violation


Latest on Amzeal News